ArticleRSC advances2026
Synthesis, multi-target evaluation and DFT analysis of 6-hydroxychromone derived hydrazones with carbonic anhydrase I-II/acetylcholinesterase inhibition and antioxidant activity.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Design, synthesis and DFT analysis of a highly selective chromenylium based fluorescent probe for cellular imaging and selective detection of sulfite ions.RSC advances · 2026Article
- Synthesis, biological evaluation and detailed computational studies of N-sulfonyl indole-based dihydrothiazoles against colorectal carcinoma.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease seems to be the result of several tumultuous processes such as cholinergic deficits associated with the abnormal metabolic status and oxidative stress that cannot be controlled effectively by single-target molecules. A complex group of agents capable of combining specific enzyme inhibition with antioxidant protection may be seen as an approach toward neuroprotection. The partial synthesis method led to the creation of a new series of chromone hydrazones (3a-p) from substituted hydrazones and 6-hydroxy-chromone. All the newly obtained hydrazones were assayed for their inhibitory activity against acetylcholinesterase (AchE) and human carbonic anhydrases (CA I and II), and their antioxidant potentials were also studied. The chromone-substituted hydrazones 3c, 3e, and 3f exhibited good inhibitory activity against AChE with IC
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.